全文获取类型
收费全文 | 263篇 |
免费 | 15篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 28篇 |
妇产科学 | 7篇 |
基础医学 | 33篇 |
口腔科学 | 15篇 |
临床医学 | 36篇 |
内科学 | 30篇 |
皮肤病学 | 7篇 |
神经病学 | 12篇 |
特种医学 | 37篇 |
外科学 | 34篇 |
综合类 | 7篇 |
预防医学 | 10篇 |
药学 | 18篇 |
肿瘤学 | 10篇 |
出版年
2023年 | 2篇 |
2022年 | 4篇 |
2021年 | 3篇 |
2020年 | 5篇 |
2019年 | 2篇 |
2018年 | 8篇 |
2017年 | 4篇 |
2016年 | 4篇 |
2015年 | 9篇 |
2014年 | 6篇 |
2013年 | 6篇 |
2012年 | 10篇 |
2011年 | 10篇 |
2010年 | 16篇 |
2009年 | 15篇 |
2008年 | 3篇 |
2007年 | 17篇 |
2006年 | 25篇 |
2005年 | 1篇 |
2004年 | 3篇 |
2003年 | 1篇 |
2002年 | 7篇 |
2001年 | 4篇 |
2000年 | 2篇 |
1999年 | 4篇 |
1998年 | 16篇 |
1997年 | 16篇 |
1996年 | 12篇 |
1995年 | 7篇 |
1994年 | 14篇 |
1993年 | 10篇 |
1992年 | 6篇 |
1991年 | 1篇 |
1989年 | 1篇 |
1988年 | 5篇 |
1987年 | 2篇 |
1986年 | 4篇 |
1985年 | 7篇 |
1984年 | 3篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1978年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
排序方式: 共有285条查询结果,搜索用时 0 毫秒
81.
C Rongen-Westerlaken E vd Born B Prahl-Andersen A v Teunenbroek P Manesse BJ Otten I vd Tweel AM Kuijpers-Jagtman HA Delemarre vd Waal NM Drayer JM Wit JL vd Brande 《Acta paediatrica (Oslo, Norway : 1992)》1993,82(4):364-368
A cephalometric study was performed in 19 patients with Turner's syndrome, aged 8.7–16.5 years. A lateral roentgencephalogram was taken before and after two years of treatment with biosynthetic growth hormone in a dose of 24 IU/m2 /week. During two years of growth hormone treatment, the mandibular length increased mainly due to vertical growth. The initially posteriorly rotated mandible showed an anterior rotation, although the normal position was not reached. The other linear measurements and angles did not change during treatment. No indications were found for an increase in the disproportionate growth or for excessive chin growth as a sign of acromegaly during growth hormone treatment. In conclusion, growth hormone treatment in patients with Turner's syndrome resulted in an increase in mandibular length, mainly due to vertical growth of the ramus and in the anterior rotation of the mandible. 相似文献
82.
83.
Suzanne GM Stomp-van den Berg Mireille NM van Poppel Ingrid JM Hendriksen David J Bruinvels Kimi Uegaki Martine C de Bruijne Willem van Mechelen 《BMC public health》2007,7(1):43
Background
Many women suffer from health problems after giving birth, which can lead to sick leave. About 30% of Dutch workers are on sick leave after maternity leave. Structural contact of supervisors with employees on maternity leave, supported by early medical advice of occupational physicians, may increase the chances of return-to-work after maternity leave. In addition, to understand the process of sick leave and return-to-work after childbirth it is important to gain insight into which factors hinder return-to-work after childbirth, as well, as which prognostic factors lead to the development of postpartum health complaints. In this paper, the design of the Mom@Work study is described. 相似文献84.
Impact of mycophenolate mofetil on recurrent rejection in kidney transplant patients 总被引:3,自引:0,他引:3
PURPOSE: Mycophenolate mofetil (MMF) has emerged as a valuable adjunctive agent in renal transplantation. However, due to intolerable adverse effects associated with MMF use in our transplant population, we have used MMF selectively in patients at high risk for recurrent graft rejection, since these patients are known to be at risk for poor long-term graft outcomes. The purpose of this study was to assess the efficacy of MMF in preventing the recurrence of acute rejection following an initial rejection episode in kidney transplant patients in the first year following transplantation. METHODS: Forty-four kidney transplant recipients were given MMF prospectively following treatment of their initial rejection episode to prevent recurrent rejection. MMF 1-2 g/d was given. Doses were adjusted based on tolerance; MMF therapy was to be continued for at least 6 months. The control group consisted of 124 consecutive kidney transplant recipients who had received standard anti-rejection therapy without the addition of MMF. Maintenance immunosuppression consisted predominantly of cyclosporine, prednisone+/-azathioprine. Anti-rejection therapy for both groups consisted of either corticosteroids (methylprednisolone 500 mg i.v. for 3 d or oral prednisone 2 mg/kg/d with rapid taper over 3 wk), OKT3 5 mg/d for 10 d or ATG 15 mg/kg/d for 10 d. All rejection episodes were confirmed by biopsy. RESULTS: The majority of rejection episodes were characterized histologically as mild or moderate. Most patients (76%) received corticosteroids for treatment of their first rejection episode. There was a 68% reduction in the incidence of recurrent rejection episodes within the first year of transplant in patients receiving MMF; only 14% of recipients receiving MMF developed recurrent rejection compared to 44% of patients in the control group (p<0.05). Approximately 50% of patients developed MMF-associated adverse effects (leukopenia, GI toxicity). Only 52% of patients remained on MMF at 6 months. One-yr graft survival was 86% in the MMF group and 89% in the control group (p>0.05). One-year patient survival was 93 and 100%, respectively (p>0.05). CONCLUSIONS: The addition of MMF to maintenance therapy for patients experiencing acute renal allograft rejection may prevent recurrent rejection episodes in the subsequent follow-up year. 相似文献
85.
炎症在启动和维持心房颤动中的地位——对研究资料的系统回顾 总被引:1,自引:0,他引:1
近年的研究显示,炎症在启动、维持心房颤动(房颤)中起非常重要的作用.美国Issac等对1995~2007年间以英文发表的有关房颤与炎症关系方面的文章,以及药物,如他汀类、血管紧张素转化酶抑制剂(ACEI)及糖皮质激素在治疗房颤中的作用方面的文章进行了系统回顾(J Am Coll Cardiol,2007, 50:2021-2028). 相似文献
86.
Denosumab (Amgen, Thousand Oaks, California, USA) is a new bone antiresorptive agent used in patients with osteoporosis or metastatic cancer to the bones. As with the bisphosphonates that are used as antiresorptive medications, denosumab has been associated with osteonecrosis of the jaws (ONJ). Over the past two years there has been an increase in the literature describing ONJ in patients receiving agents such as denosumab. Due to promising study results that demonstrate the effectiveness of denosumab in avoiding skeletal complications related to osteoporosis and metastatic bone disease, more patients will receive denosumab in the future. It is reported that this has the potential to become a comparable challenge to bisphosphonate related osteonecrosis of the jaws (BRONJ) for clinicians. This article describes the management of two patients that developed ONJ while receiving denosumab, reviews the incidence of ONJ associated with denosumab, and contrasts the pharmacokinetics of denosumab and the bisphosphonates. The importance of avoiding interventional dental treatment until denosumab has been withdrawn for six months cannot be overstated. 相似文献
87.
PD Scheffer-Marinus TP Links WD Reitsma NM Drayer 《Acta paediatrica (Oslo, Norway : 1992)》1999,88(4):384-388
This study was conducted to analyse the effect of childhood-onset diabetes mellitus on adult height. The height at time of diagnosis of 35 children with insulin-dependent diabetes mellitus (IDDM) was compared with growth reference data. Predictions of the adult height were made at the time of diagnosis using the target height and the Tanner-Whitehouse II method. The adult height was compared with both the predicted values and the height of healthy adults. The height at time of diagnosis of the prepubertal children was increased compared with growth reference data, in contrast to pubertal children who had normal heights. Only the prepubertal boys were taller at time of diagnosis. The adult height of the prepubertal patients was taller than growth reference data. The mean adult height in all patients did not differ significantly from the predicted heights. In conclusion, the increased height at the start of IDDM in prepubertal children persists until adulthood. 相似文献
88.
In the oral cavity, the immune system is constantly exposed to unique tissue‐specific signals, including a rich community of commensal microbes and their metabolites, continuous tissue damage from mastication, and antigens from food and airborne particles. How this unique combination of signals participates in the training of specialized immunity at this site is not well understood, yet imbalance of local responses is linked to tissue‐specific disease susceptibilities with the prototypic disease being periodontitis. However, the oral mucosa is also well recognized as a site where systemic inflammatory and autoimmune diseases often manifest, indicating that systemic immune deregulation is reflected in the function of the oral immune system. This commentary will discuss both aspects of compartmentalized and systemic immunity at the oral mucosa. 相似文献
89.
90.